TDACTranslational Development Acquisition Corp.(TDAC)Stock Analysis

AI analysis on 2,800+ stocks →
FinancialsNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1926599TDAC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TDAC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Translational Development Acquisition Corp. (TDAC), a Financials sector company. TDAC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Translational Development Acquisition Corp. reports net income of $1.3M, free cash flow of $-305.2K. Top institutional holders of TDAC by reported 13-F value include Magnetar Financial, WOLVERINE ASSET MANAGEMENT, AQR Arbitrage, based on the most recent SEC filings. TDAC trades on the Nasdaq exchange and files with the SEC under CIK 1926599. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TDAC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Translational Development Acquisition Corp. directly from SEC EDGAR.

Net Income

Q1 2026

$1.3M

Free Cash Flow

Q1 2026

$-305.2K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+9059.7% YoY
$6.4MFY 2025
FY22 FY23 $-485.6KFY24 $-71.0KFY25 $6.4M

Operating Income

-381.0% YoY
$-944.5KFY 2025
FY22 FY23 $-485.6KFY24 $-196.4KFY25 $-944.5K

Total Assets

+3.8% YoY
$181.7MFY 2025
FY22 FY23 $2.0KFY24 $175.0MFY25 $181.7M

Op. Cash Flow

+28.5% YoY
$-608.4KFY 2025
FY22 FY23 $-204.00FY24 $-851.4KFY25 $-608.4K

AI Insight: TDAC Financial Trends

TDAC remains a shell company with minimal operating activity and negative equity throughout the reporting period.

Net income consistently positive but negligible at $1–2M per quarter, Q1 2025–Q4 2025, indicating minimal business operations.

Operating income and operating cash flow remain at or near zero across all periods, confirming lack of meaningful business.

Equity negative throughout: –$6M in Q1–Q3 2025, declining to –$7M by Q4 2025 and Q1 2026.

Negative shareholder equity widened $1M from Q3 2025 to Q4 2025, signaling ongoing capital erosion with no revenue or operational progress.

No revenue reported across entire period; no indicators of SPAC merger, business combination, or acquisition completion.

AI Insight: TDAC Ratio Trends

TDAC's ROA deteriorated sharply to 2.9% in Q1 2026, erasing gains from prior three quarters and signaling operational headwinds.

ROA rose steadily from 3.4% in Q1 2025 to 3.7% in Q3 2025, then contracted to 2.9% in Q1 2026—lowest in dataset.

TTM ROA at 3.4% masks Q1 2026 weakness; prior four quarters showed modest uptrend before latest quarter reversal.

Q1 2026 ROA decline of 0.6pp is first quarterly drop since Q1 2025. Monitor whether seasonality or structural deterioration.

Limited data (only ROA and TTM disclosed); absence of margin, profitability, and leverage metrics restricts visibility into drivers.

Get alerted when TDAC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Translational Development Acquisition Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put TDAC on your watchlist

Track score changes the day Translational Development Acquisition Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is TDAC a good stock to buy?

13F Pro's AI-powered analysis of Translational Development Acquisition Corp. (TDAC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Financials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TDAC are available on the TDAC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TDAC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TDAC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Translational Development Acquisition Corp.'s investment landscape.